Fig. 1From: Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trialEfficacy analyses of combination treatment with afatinib and osimertinib. (a) Waterfall plot of evaluable patients (n = 12). The overall response rate was 7.7%. (b) Kaplan–Meier curve analysis of PFS. The median PFS duration was 2.4 monthsBack to article page